Juvenescence
Juvenescence is a clinical-stage drug development company focused on extending healthy lifespan through innovative medicines that target core aging mechanisms. Their business model emphasizes early disease intervention and prevention, with a pipeline of multiple clinical medicines expected to enter Phase I or II trials by 2025. The company differentiates itself by integrating AI and data science in drug development, aiming to deliver first-in-class therapies for age-related conditions. With a leadership team boasting over 150 years of combined pharmaceutical R&D experience, Juvenescence is positioned as a leader in the longevity biotech space, committed to transforming how we age and ensuring that added years are healthy and fulfilling.
Juvenescence
Juvenescence is a clinical-stage drug development company focused on extending healthy lifespan through innovative medicines that target core aging mechanisms. Their business model emphasizes early disease intervention and prevention, with a pipeline of multiple clinical medicines expected to enter Phase I or II trials by 2025. The company differentiates itself by integrating AI and data science in drug development, aiming to deliver first-in-class therapies for age-related conditions. With a leadership team boasting over 150 years of combined pharmaceutical R&D experience, Juvenescence is positioned as a leader in the longevity biotech space, committed to transforming how we age and ensuring that added years are healthy and fulfilling.